Repositioning Candidate Details
| Candidate ID: | R0019 |
| Source ID: | DB00063 |
| Source Type: | approved; investigational |
| Compound Type: | biotech |
| Compound Name: | Eptifibatide |
| Synonyms: | Eptifibatide; Integrelin; Intrifiban |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. |
| CAS Number: | 188627-80-7 |
| Molecular Weight: | |
| DrugBank Indication: | For treatment of myocardial infarction and acute coronary syndrome. |
| DrugBank Pharmacology: | Eptifibatide is an anti-coagulant that selectively and reversibly blocks the platelet glycoprotein IIb/IIIa receptor. |
| DrugBank MoA: | Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner. |
| Targets: | Integrin beta-3 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I08 | 114 | Cardiovascular system disease | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system | disease of anatomical entity | Details |